December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
1 citations
,
September 2015 Gefitinib treatment led to unexpected hair growth in two lung cancer patients.
November 2023 in “SKIN The Journal of Cutaneous Medicine” 150 citations
,
June 1999 in “Oncogene” 121 citations
,
December 2001 in “American Journal of Dermatopathology” TB and BCC tumors show similar follicular differentiation patterns.
6 citations
,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
32 citations
,
September 2015 in “Dermatology” Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
27 citations
,
July 2013 in “Journal of Investigative Dermatology” Revertant cell therapy shows promise for treating type XVII collagen deficiency, but better cell selection methods are needed.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
2 citations
,
March 2013 in “Phytotherapy Research” Ascorbigen increases hair cell growth in a lab setting but does not prevent hair loss from chemotherapy in mice.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
33 citations
,
January 2019 in “Acta Dermato Venereologica” Dupilumab may help regrow hair in people with atopic dermatitis.
35 citations
,
January 2004 in “European journal of oncology nursing” Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.
12 citations
,
December 1987 in “Cancer Chemotherapy and Pharmacology” Vitamin E in the diet might help protect against hair loss caused by the chemotherapy drug doxorubicin in rabbits.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
January 2022 in “eJournal Kedokteran Indonesia” Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.
January 2023 in “Figshare” Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
January 2024 in “Wiadomości Lekarskie” Enhancing immune response can improve cancer treatment effectiveness.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
January 2023 in “Figshare” Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.
March 2026 in “Frontiers in Immunology” Pulsed electric field treatment may help the immune system fight liver tumors.
7 citations
,
July 2020 in “Pigment cell & melanoma research” RT1640 treatment reverses gray hair and promotes hair growth in mice.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
21 citations
,
August 1960 in “British journal of dermatology/British journal of dermatology, Supplement” Endoxan often causes hair loss, which usually starts in the third week of treatment.
January 2023 in “European journal of gynaecological oncology” KRT17 may be a new target for endometrial cancer treatment because it helps cancer cells move and form new blood vessels.